To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
BEIJING, April 16 (Reuters) – Two COVID-19 vaccine candidates developed by units of China National Biotec Group (CNBG) to target the Omicron variant were approved for clinical trials as boosters in Hong Kong, the Sinopharm subsidiary said on Saturday.
Scientists worldwide are racing to study upgraded injections against Omicron, as data indicated that antibodies elicited by vaccines based on older strains show weaker activity to neutralize the highly transmissible variant.
The two candidates, both containing inactivated or “killed” Omicron virus and similar to the two Sinopharm vaccines in use in China, will be tested in adults who have already received two or three vaccine doses, CNBG said in a statement.
It did not specify which vaccine products the trial participants would have received before taking the experimental booster, or how many subjects would be recruited.
A Chinese study showed that a fourth dose of BBIBP-CorV, an existing Sinopharm vaccine, did not significantly lift antibody levels against Omicron when administered six months after a third booster dose to a regular two-dose regimen.
While the fourth dose did restore antibody levels to around the peak levels that followed the third dose, researchers said new vaccines would offer a better alternative as future boosters.
